Sign in
CompletedPhase 4

Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD

Key facts

Who runs it
VA Office of Research and Development
Where
Buffalo, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 4
People taking part
53 people enrolled
Started
1 Dec 2019
Ended
30 Mar 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • eszopiclone
  • Brief behavioral therapy for insomnia
Record updated
21 October 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Age >18 years and <65 years old
  • Diagnosis of PTSD as determined by the intake conducted through the PTSD Clinic or the Mental Health Clinic
  • Documented obstructive sleep apnea by polysomnography (AHI 5 or more/hour) who are non-adherent to CPAP as defined by device usage of less than 4 hours per night
  • Chronic ( 3 months' duration) insomnia disorder
  • Psychotherapeutic treatment stable for at least 4 weeks prior to randomization
  • Capable of giving informed consent

Who cannot take part

  • Use of potent cytochrome p450 3A4 inhibitor medications (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) and is unwilling or it is clinically contraindicated to stop the medication
  • History of narcolepsy and/or cataplexy
  • Treatment for seizure disorders
  • History of clinically significant hepatic impairment
  • History of hypersensitivity, intolerance, or contraindication to eszopiclone
  • Diagnosis of current schizophrenia or schizoaffective disorder
  • Diagnosis of a substance dependence/abuse disorder in the past year
  • History of complex nocturnal behaviors while using eszopiclone
  • Severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior which poses an immediate danger to patient or others
  • Diagnosis of bipolar disorder
  • Insomnia secondary to pain
  • Pregnant or lactating
  • Unwilling to try or use CPAP
  • Consumption of more than two alcoholic beverages per night
  • Documented or self-reported resolution of insomnia from current behavioral or pharmacological treatment of insomnia

Where in United States

  • VA Western New York Healthcare System, Buffalo, NYBuffalo, United States

About the trial

What the trial wants to find out

Obstructive sleep apnea (OSA) is commonly reported in Veterans with post-traumatic stress disorder, which can potentiate symptoms of anxiety and depression, daytime symptoms and worsen nightmares. Continuous positive airway pressure (CPAP) is the most effective therapy but adherence to treatment is suboptimal. Insomnia is considered a barrier to long-term adherence. The overarching theme of the proposal is to compare the effectiveness of cognitive behavioral therapy for insomnia (CBT) plus eszopiclone, a nonbenzodiazepine hypnotic, versus CBT alone in Veterans with PTSD who are diagnosed with both OSA and insomnia, using a randomized, clinical trial, on sleep quality of life, PTSD severity, and CPAP adherence.

The 2 groups in the trial

  • BBTI plus eszopicloneTreatment being tested

    participants randomized to the combination therapy will receive eszopiclone 2 mg orally at bedtime or placebo starting with the BBTI sessions for a period of 2 weeks in combination with 4 sessions of BBTI over 4 weeks.

    Treatment: eszopiclone and Brief behavioral therapy for insomnia

  • Brief Behavioral Therapy for InsomniaExisting treatment, for comparison

    participants randomized to BBTI will receive 4 sessions of BBTI over 4 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pragmatic Randomized Comparator Trial of Eszopiclone and Brief Behavioral Therapy for Insomnia in CPAP Non Adherent Veterans With PTSD and Complex Insomnia
Publications
Record updated
21 October 2025